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Everolimus displays antiproliferative effects on cancer cells, yields antiangiogenic activity in established tumours, and shows synergistic
activity with paclitaxel in preclinical models. This study assessed the safety and the pharmacokinetic interactions of everolimus and
paclitaxel in patients with advanced malignancies. Everolimus was dose escalated from 15 to 30mg and administered with paclitaxel
80mgm
 2 on days 1, 8, and 15 every 28 days. Safety was assessed weekly, and dose-limiting toxicity (DLT) was evaluated in cycle 1.
A total of 16 patients (median age 54.5 years, range 33–69) were entered; 11 had prior taxane therapy for breast (n¼5), ovarian
(n¼3), and vaginal cancer (n¼1) or angiosarcoma (n¼2). Grade 3 neutropenia in six patients met the criteria for DLT in two
patients receiving everolimus 30mg weekly. Other drug-related grade 3 toxicities were leucopenia, anaemia, thrombocytopenia,
stomatitis, asthenia, and increased liver enzymes. Tumour stabilisation reported in 11 patients exceeded 6 months in 2 patients with
breast cancer. Everolimus showed an acceptable safety profile at the dose of 30mg when combined with weekly paclitaxel
80mgm
 2, warranting further clinical investigation.
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The mammalian target of rapamycin (mTOR) is an important
kinase downstream in the PI3-kinase/Akt signalling pathway. It
modulates signals from growth factors and intracellular sensors of
nutrients and hypoxia to control translation of proteins involved
in cellular growth, proliferation, and responses to nutrient
deprivation and hypoxic stress, resulting in the stimulation of
angiogenesis, facilitation of G1–S transition of the cell cycle, and
inhibition of radiation or cytotoxic drug-induced apoptosis in a
variety of human tumours (Faivre et al, 2006). Cancer cells
commonly have mutations and/or overexpression of several
signalling molecules, resulting in the activation of mTOR and its
substrates S6K1 and 4E-BP1. For example, the HER2 over-
expression observed in about one-third of breast cancers is
associated with activation of PI3-kinase/Akt/mTOR signalling
(Bacus et al, 2002; Zhou et al, 2004), resistance to stress-induced
apoptosis (Bacus et al, 2002), and tumour aggressiveness (Cobleigh
et al, 1999; Zhou et al, 2004). Activation of the PI3-kinase/Akt/
mTOR signalling pathway may be inhibited by rapamycin, which
blocks mTOR activation, resulting in the inhibition of tumour
growth (see reviews by Faivre et al, 2006; Georgakis and Younes,
2006).
Everolimus (RAD001) is an oral mTOR inhibitor derived from
rapamycin, which blocks the activation of S6K1 and 4E-BP1,
thereby inhibiting cell growth, proliferation, and G1–S transition,
and inducing apoptosis (Boulay et al, 2004). Everolimus displays
direct effects on growth and proliferation of cancer cells and
inhibits angiogenesis by preventing the proliferation of endothelial
cells in human tumour xenografts (Beuvink et al, 2001; Lane et al,
2003). In single-agent phase I studies of everolimus performed in
patients with advanced cancers, a safe toxicity profile along with
evidence of sustained tumour stabilisation at weekly doses of 10–
70mg was shown (O’Donnell et al, 2008; Tabernero et al, 2008).
Dose-limiting toxicities (DLTs) observed at 70mg included grade 3
stomatitis, neutropenia, and hyperglycaemia (Tabernero et al,
2008). Consistent inhibition of S6K1 activity in peripheral blood
mononuclear cells was seen with doses X20mg per week and was
sustained for at least 7 days at doses X20mg per week (O’Donnell
et al, 2008). Furthermore, immunohistochemical analysis in paired
tumour tissue biopsies taken before and during weekly dosing (20,
50, or 70mg) confirmed inhibition of S6K1 at doses X20mg
(Tabernero et al, 2008).
Paclitaxel remains a standard treatment for a variety of cancers,
including lung, breast, head and neck, and ovary, and may be
administered weekly to reduce haematological toxicity either alone
or in combination with other anti-tumour agents on an every-week
(Green et al, 2005; Le et al, 2006; Schuette et al, 2006; Yamamoto
et al, 2006) or a weekly for 3 weeks monthly schedule (Perez et al,
2005; Yeh et al, 2005; Ramalingam et al, 2006; Stathopoulos et al,
2007). Several tumour types that display sensitivity to paclitaxel
also show activation of the PI3-kinase/Akt/mTOR signalling
pathway (Shayesteh et al, 1999; Hu et al, 2000; Perez-Tenorio
et al, 2002; David et al, 2004; Samuels et al, 2004; Saal et al, 2005).
Paclitaxel resistance appears multifactorial, involving overexpres-
sion of P-glycoprotein, mutation of b-tubulin, and defects of
apoptosis (Yusuf et al, 2003). There is also consistent evidence that
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sthe PI3-kinase/Akt/mTOR signalling pathways may be associated
with resistance to taxanes and other drugs acting on microtubules.
In cancer cells, inhibition of the PI3-kinase/Akt/mTOR signalling
pathway (Hu et al, 2002; Yu et al, 2005), including inhibition of
mTOR with rapamycin, was shown to counteract Akt-mediated
resistance to drugs inhibiting tubulin (Vanderweele and Rudin,
2005) and to restore apoptosis (Faried et al, 2006).
In vivo combinations of everolimus with paclitaxel showed
additive and synergistic effects in tumour models but with a
schedule effect, in that administration of everolimus 1 day before
or after paclitaxel reduced anti-tumour activity (O’Reilly et al,
2003). These preclinical data served as a rationale to further
investigate the safety and potential pharmacokinetic interactions
of everolimus in combination with paclitaxel in patients with
tumours potentially sensitive to paclitaxel-based chemotherapy.
To avoid effects related to scheduling and accumulation, ever-
olimus and paclitaxel were administered together on the first day
of each week, and in week 4 of each cycle treatment, it was omitted
to allow recovery of cells from mTOR inhibition.
MATERIALS AND METHODS
This open-label dose-escalation study was approved by the French
National Ethics Committee and was conducted in accordance with
the Declaration of Helsinki Principles and Good Clinical Practice.
A signed informed consent was required of each patient.
Eligibility criteria
Eligible patients were at least 18 years of age with pathologically
confirmed locally advanced or metastatic cancer refractory to or
unsuitable for standard chemotherapy, but they were potentially
able to benefit from paclitaxel chemotherapy. Life expectancy
was X6 months with a World Health Organization (WHO)
performance status of 0–2. Patients also had adequate
bone marrow (absolute neutrophil count X1.5 10
9l
 1, platelets
X100 10
9l
 1, haemoglobin 410g per 100ml), liver function
(serum transaminase p3 times upper limit of normal (ULN),
serum albumin and bilirubin within reference ranges), and kidney
function (creatinine p1.5 times ULN).
Patients were ineligible if they had primary or metastatic central
nervous system cancer, a history of HIV seropositivity, or active
bleeding diathesis; were taking oral anti-vitamin K medication
(except low-dose coumadin); had uncontrolled infection, impaired
gastrointestinal function, or disease that might alter absorption of
everolimus; or had received an investigational drug within the
previous 30 days. Women who were pregnant, breast-feeding, or
able to conceive but unwilling to practice effective contraception,
and patients with known Cremophor allergy were also excluded.
Study drug administration and monitoring
Everolimus (RAD001; Novartis Pharmaceuticals, Basel, Switzerland)
and paclitaxel (Bristol-Myers Squibb Pharmaceuticals Ltd, New
York, NY, USA) were administered on days 1, 8, and 15 on an
every-28-day cycle for up to 6 cycles. Everolimus was given orally
immediately before paclitaxel, which was administered by
intravenous infusion over 60min. Patients receiving at least one
dose of study drug medications were evaluated weekly for safety
using the National Cancer Institute Common Toxicity Criteria
version 2.0. Safety assessments consisted of clinical examinations
and scheduled laboratory evaluations and electrocardiograms. The
paclitaxel–everolimus combination was interrupted on the occur-
rence of any grade 3 non-haematological toxicity or grade X2
thrombocytopenia or neutropenia until recovery to grade p1.
Treatment with the combination was discontinued on any grade 4
toxicity or failure to return to grade p1 within 2 weeks.
Prophylaxis of emetic and allergic reactions to paclitaxel using
ondansetron, granisetron, and steroids was allowed. The con-
comitant use of any drugs that may interfere with cytochrome
CYP450-3A was discouraged. After paclitaxel discontinuation at
the completion of six cycles, everolimus could be maintained
weekly until tumour progression. Anti-tumour activity was
assessed using Response Evaluation Criteria in Solid Tumors.
Dose escalation and definition of DLT
Because everolimus could potentially increase exposure to
paclitaxel and, at higher doses than used in this study, had shown
significant haematological toxicity, the safety of the combination
was explored in patients in whom the standard weekly dose of
paclitaxel 80mgm
 2 was combined initially with one-half the
single-agent recommended dose of everolimus (15mg weekly, dose
level 1) and then escalated to 30mg weekly (dose level 2). Dose-
limiting toxicity was defined as occurring during the first 28-day
cycle, suspected of being drug related, and included any grade 4
toxicity, any grade 3 non-haematological toxicity despite pre-
ventive therapy, or grade X2 neutropenia, or thrombocytopenia
failing to revert to grade p1 within 2 weeks. Three patients were
entered per dose level, with expansion to six patients if one of three
patients experienced DLT. If DLT occurred in none of three or no
more than one of six patients in dose level 1, doses would be
escalated to dose level 2. Dose-limiting toxicity in more than one of
three or more than two of six patients would be considered
unacceptable. After the highest well-tolerated dose of everolimus
(15 or 30mg) in combination with paclitaxel was established, the
size of this cohort would be expanded to 12 patients to obtain
additional safety information on cumulative toxicity. With a
sample size of 12 patients, the expanded cohort had a probability
of 72 and 99% of detecting any toxicity that occurs with an
incidence of 10 and 30%, respectively.
Pharmacokinetic measurements
In week 1 of cycle 1, blood samples were taken together to measure
pharmacokinetic parameters of both everolimus and paclitaxel. At
cycle 2, everolimus was withheld on day 1, allowing the
determination of blood levels of paclitaxel alone, without
interference from everolimus, which shows a terminal half-life of
about 30h as a single agent. Pharmacokinetic parameters of
everolimus were determined in week 2 of cycle 2, 1 week following
the last administration of paclitaxel, which displays a terminal
half-life of about 10h as a single agent. For paclitaxel, sampling
was carried out before and at the end of the infusion and at 15 and
30min, and 1, 2, 4, 9, 24, 36, 48, and 96h after completion of the
infusion. For everolimus, sampling was carried out predose and 1,
2, 4, 6, 12, 24, 48, 96, and 168h after administration. Everolimus
was measured in whole blood by liquid chromatography–mass
spectrometry after liquid extraction, its lower limit of quantifica-
tion being 0.368ngml
 1. Paclitaxel was measured in plasma by
high-pressure liquid chromatography with ultraviolet detector,
lower limit of quantification being 10 ngml
 1. Pharmacokinetic
parameters were derived by standard non-compartmental methods
of analysis (WinNonlin Pro 5.0). The measured parameters
included the maximum plasma concentration (Cmax), time to
reach Cmax (tmax), and the truncated area under the time–
concentration curve (AUClast).
RESULTS
General
A total of 16 patients with advanced solid tumours were enrolled in
this study (Table 1). Most were considered heavily pre-treated,
with a median of three prior chemotherapy regimens (range 0–10
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sregimens). None of the three patients entered at dose level 1
experienced DLT in cycle 1, allowing escalation to dose level 2. At
dose level 2, none of the first 6 patients experienced DLT in cycle 1;
thus, this cohort was expanded (Table 2) to 13 patients (one
patient who experienced tumour progression on day 8 of cycle 1
was not fully evaluable for safety). Among 12 patients evaluable for
toxicity at dose level 2, 2 patients experienced DLTs; one with
grade 3 neutropenia, the other with grade 3 neutropenia and
grade 2 thrombocytopenia. The toxicities recovered within 2 weeks
but were interpreted as de facto DLTs, because the paclitaxel dose
was immediately reduced by 25% for subsequent cycles in
conformity with the manufacturer’s recommendations. Median
duration of everolimus and paclitaxel at dose level 2 was
three cycles; three patients completed six cycles, including two
patients with metastatic breast cancer who continued to receive
single-agent everolimus for 8 and 18 weeks after paclitaxel
discontinuation.
Safety No toxicity-related death was reported. The most fre-
quently reported adverse events of any grade irrespective of
causality occurring in any treatment cycle were asthenia (81.3%),
neutropenia (62.5%), alopecia and anaemia (each 43.8%), and
stomatitis, nausea, and pyrexia (each 37.5%). Grade 3/4 adverse
events reported in 11 patients included 1 patient with an unrelated
grade 4 necrosis of the toe. The most frequently reported drug-
related toxicities (Table 3) included neutropenia (56.3%), alopecia
and asthenia (each 43.8%), and anaemia and stomatitis (each
37.5%). Thirteen drug-related grade 3 toxicities reported in eight
patients, all at dose level 2, included neutropenia in six patients
(37.5%), leucopenia in two patients (12.5%), and anaemia,
thrombocytopenia, asthenia, stomatitis, and increased alanine
aminotransferase levels in individual patients. No drug-related
grade 4 toxicity was reported. Serious adverse events occurred in
six patients, four directly linked with tumour progression; the
other two included a case of grade 3 erysipelas and grade 1
neutropenia in a patient with skin melanoma, and grade 3
interstitial pneumonitis at cycle 6 in another with metastatic breast
cancer. In the latter patient, interstitial pneumonitis was confirmed
by bronchoscopy and was reversible under treatment with
corticosteroids.
Pharmacokinetics Blood samples were obtained from 11 patients,
including 3 patients treated at dose level 1 and 8 patients at dose
level 2. Three patients at dose level 2 did not provide blood
samples for determination of everolimus pharmacokinetics. In
addition, one patient treated at dose level 2 displayed a threefold
increase of everolimus AUC that was found to be related to
concomitant medication with fluconazole, invalidating any possi-
ble assessment of drug interaction between paclitaxel and
everolimus.
Representative pharmacokinetic curves of patients treated at
dose level 2 are shown in Figure 1, and the main pharmacokinetic
parameters of everolimus and paclitaxel are shown in Table 4. As
shown, no meaningful change in tmax, Cmax, and AUClast of
paclitaxel and everolimus was detectable when the drugs were
given in combination.
Table 1 Patient characteristics
Age, years
Median 54.5
Range 33–69
Sex, n
Female 13
Male 3
Race, n
Caucasian 15
Black 1
WHO performance status, n
04
11 0
22
Primary site, n
Breast 5
Ovarian 3
Angiosarcoma 2
Melanoma 1
Other
a 5
Stage, n
IV 15
Unknown 1
Time since diagnosis, n(%)
o1 year 1 (6.3)
1–o2 years 3 (18.8)
X3 years 2 (12.5)
2–o3 years 10 (62.5)
Prior therapy, n
Taxanes 11
Radiation 8
Other chemotherapy 15
Prior chemotherapy regimens, n
12
24
429
WHO¼World Health Organization.
aOne each in dose level 2: thyroid carcinoma,
mixed testicular (mature embryonic and immature teratoma) cancer, abdominal
liposarcoma, vaginal cancer, cholangiocarcinoma.
Table 2 Treatment administration by dose level
Dose level 1
everolimus
15mg
Dose level 2
everolimus
30mg All
Treated, n 31 3 1 6
Discontinued, n
Due to AEs 0 1 1
Due to PD, tumour
complications
31 1 1 4
For other reason 0 1 1
Cycles completed,
a n
00 1 1
10 1 1
21 3 4
30 4 4
42 1 3
50 0 0
6
b 03 3
Mean everolimus treatment
duration, weeks
12.6 13.8 13.6
Median everolimus
treatment duration, weeks
14.1 11.9 12.5
Range, weeks 9–15 1–41 1–41
Dose interruptions in any
cycle, n (%)
1 (33.3) 7 (53.8) 8 (50.0)
AE¼adverse event; PD¼progressive disease.
aCycles completed refers to the
number of combined everolimus with paclitaxel 4-week cycles.
bAmong the three
patients completing six cycles of everolimus 30mg with paclitaxel therapy, the
customary maximum for paclitaxel, two patients with metastatic breast cancer
continued to receive everolimus for 8 and 18 weeks.
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sResponse to therapy No objective response was observed.
Sustained tumour stabilisation for more than 4 months was
observed in six patients, including those with breast cancer (two
patients), ovarian carcinoma (two patients), thyroid carcinoma
(one patient), and liposarcoma (one patient). In two patients with
metastatic breast cancer treated at dose level 2, tumour stabilisa-
tion that lasted 46 months exceeded the duration of tumour
stabilisation previously recorded with docetaxel therapy (3.7 and
3.5 months).
DISCUSSION
Genetic defects in cancer cells expressed as the constitutive
activation of growth factor signalling pathways provide stimula-
tion for continued cell growth, survival, and resistance to
chemotherapy. In tumours addicted to this growth factor
stimulation, chemotherapy combined with mTOR inhibition has
shown synergistic anti-tumour effects. For example, data have
shown that rapamycin and everolimus can enhance the anti-
tumour activity of paclitaxel (O’Reilly et al, 2003; Mondesire et al,
2004; Faried et al, 2006; Aissat et al, 2007; Haritunians et al, 2007)
in a manner related in occurrence and extent to the tumour, dose,
and interestingly, the sequence of administration of the mTOR
inhibitor and paclitaxel (O’Reilly et al, 2003; Mondesire et al, 2004;
Faried et al, 2006; Aissat et al, 2007). In vitro, paclitaxel treatment
before mTOR inhibition produced greater enhancement of
apoptosis than treatment after or simultaneously with the mTOR
inhibitor, which may reflect a conflict between the slowing of the
cell cycle through the G1–S transition by mTOR inhibition and the
requirement that cells be in G2–M transition for paclitaxel-
induced apoptosis (Mondesire et al, 2004; Aissat et al, 2007).
Alternatively or in addition, enhancement of cytotoxicity may
directly involve p70S6 kinase, which is activated by mTOR. Direct
inactivation of p70S6 kinase in mitotic breast and ovarian cancer
by paclitaxel has been proposed as a mechanism through which
paclitaxel may exert an anti-tumour effect (Le et al, 2003). p70S6
kinase inactivates the pro-apoptotic factor BAD; mTOR inhibitors
or paclitaxel may promote apoptosis by preventing this inactiva-
tion. Consistent with these mechanisms, it has been shown that
breast cancer cells resistant to the growth inhibiting effects of
rapamycin are also resistant to its chemosensitising effects
(Mondesire et al, 2004), and sequence-dependent enhancement
of paclitaxel cytotoxicity has also been seen with gefitinib and
trastuzumab, agents that like mTOR inhibitors inhibit growth
factor signal transduction (Lee et al, 2002; Magne ´ et al, 2002).
However, in another study with cervical cancer cells, treatment
with rapamycin preceding paclitaxel produced the more favour-
able result (Faried et al, 2006), suggesting that sequence
dependency may be influenced by different mechanisms in other
types of cancer. Inhibition of protein synthesis by mTOR
inhibition may additionally contribute to apoptosis by preventing
repair of paclitaxel-induced cell damage (Aissat et al, 2007). The
extent to which sequence dependency translates in vivo is also not
clear. In one study, simultaneous treatment with everolimus and
paclitaxel produced the greatest enhancement of paclitaxel activity
(O’Reilly et al, 2003), whereas in another study with xenografts
derived from breast cancer cells in which sequence effects were
seen in vitro, no sequence effects were observed in vivo (Mondesire
et al, 2004). In this trial based on our earlier work (O’Reilly et al,
2003), everolimus was administered weekly immediately before
paclitaxel infusion to avoid or minimise scheduling effects.
In a report on the pharmacodynamics of weekly paclitaxel in
cervical cancer patients, paclitaxel could be detected in tissue for
up to 6 days and could induce apoptosis for up to 1 week after
treatment, but after 2 weeks, it could no longer be detected in the
tumour (Mori et al, 2007). The selection of 30mg per week as the
dosage for everolimus was based on the results of a phase I study
in which single doses of everolimus of up to 30mg had been shown
to be satisfactorily safe and capable of inhibiting a biomarker
indicative of target activity (S6K1 activity in peripheral blood
mononuclear cells) (O’Donnell et al, 2008). Furthermore, based on
the assumption that to be efficacious, the drug should achieve
target inhibition that is at least as great as that associated with
efficacy in the rat model (Tanaka et al, 2008), and accepting the
modelling assumption of a similar pharmacokinetic–pharmaco-
Table 3 Drug-related toxicity of everolimus in combination with paclitaxel (reported in 41 patient or of grade 3)
Dose level 1 everolimus 15mg Dose level 2 everolimus 30mg All
n¼3 n¼13 N¼16
All Grade 3 All Grade 3 All Grade 3
Any 3 — 11 8 14 8
Neutropenia 2 — 7 6 9 6
Alopecia 1 — 6 — 7 —
Asthenia 1 — 6 1 7 1
Anaemia 2 — 4 1 6 1
Stomatitis 1 — 5 1 6 1
Leucopenia 1 — 4 2 5 2
Myalgia 1 — 4 — 5 —
Paresthesia 1 — 3 — 4 —
Thrombocytopenia 0 — 4 1 4 1
Arthralgia 0 — 3 — 3 —
Erythema 0 — 3 — 3 —
Nausea 2 — 1 — 3 —
Skin lesions 0 — 3 — 3 —
Abdominal pain (upper) 1 — 1 — 2 —
Diarrhoea 1 — 1 — 2 —
Headache 1 — 1 — 2 —
Pruritus 0 — 2 — 2 —
Pyrexia 1 — 1 — 2 —
Vomiting 1 — 1 — 2 —
ALT increase 0 — 1 1 1 1
ALT¼alanine aminotransferase.
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sdynamic relationship for tumour in patients and in rats, 20–30mg
was identified as the minimal weekly dose. In addition,
immunohistochemical analyses in paired tumour biopsies taken
before and during weekly dosing (20, 50, or 70mg) confirmed
inhibition of S6K1 at doses X20mg (Tabernero et al, 2008).
Consequently, in this study, a weekly dose of everolimus, 15 or
30mg for 3 weeks followed by a 1-week rest period, was selected as
likely to allow adequate inhibition of mTOR signalling, with a
period of recovery between doses in the event that relief of mTOR
inhibition or paclitaxel exposure enhances the apoptosis-inducing
effects of this combination. A lower paclitaxel dose intensity with
the 3-weeks-on, 1-week-off schedule compared with a continuous
weekly schedule may compromise anti-tumour activity, although
paclitaxel regimens with doses of 70–100mgm
 2 administered for
3 weeks of each 4-week cycle have been used in combination with
cytotoxic agents in patients with advanced cancers with encoura-
ging evidence of anti-tumour activity and acceptable tolerability
(Perez et al, 2005; Yeh et al, 2005; Ramalingam et al, 2006;
Stathopoulos et al, 2007). With this regimen, we have shown that
the toxicity of paclitaxel was not enhanced in combination with
everolimus.
The most commonly reported drug-related adverse events were
haematological toxicity, alopecia, asthenia, and stomatitis. Inter-
stitial pneumonitis has been recognised as being associated with
sustained treatment with rapamycin and other rapamycin
derivatives (Pham et al, 2004; El-Maraghi et al, 2006). Pulmonary
toxicity is a potential toxicity associated with the use of newer
anti-neoplastic agents (Vahid and Marik, 2008). In this study,
interstitial pneumonitis was of short duration and recovered under
corticosteroid therapy. Interestingly, there was no apparent
pharmacokinetic drug interaction between everolimus and pacli-
taxel. Although both drugs are metabolised by CYP450-3A,
paclitaxel may be preferentially metabolised by CYP2C8. Further,
steroids used in paclitaxel therapy such as dexamethasone, a weak
inducer of CYP3A4, did not appear to affect everolimus.
Everolimus and paclitaxel may be co-administered with
manageable toxicity. Everolimus 30mg can be safely administered
with paclitaxel 80mg on a weekly schedule with dosing for 3 weeks
on 4-week cycles for several months in human malignancies. No
pharmacokinetic interactions were apparent, and neutropenia was
the only toxicity considered dose limiting. It is noteworthy that
previous attempts to combine mTOR inhibitors with cytotoxic
agents were associated with an increased incidence of toxicity that
included dose-limiting diarrhoea and stomatitis with 5-fluoro-
uracil (Punt et al, 2003) and thrombocytopenia with gemcitabine
(Pacey et al, 2004). In this regard, the feasibility of combining
everolimus with paclitaxel at clinically effective doses of each agent
and the delayed tumour progression observed in this heavily pre-
treated population warrant further investigation in paclitaxel-
sensitive tumours. Preliminary results of a phase I study
combining everolimus and paclitaxel with trastuzumab in patients
with trastuzumab-resistant breast cancer have been encouraging,
in that the combination was adequately tolerated with a high rate
of response (46%) in a population pre-treated with both
trastuzumab and taxanes (Andre ´ et al, 2008).
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Figure 1 Pharmacokinetic profiles of everolimus in combination with
paclitaxel. (A) Mean plasma concentration of everolimus following oral
administration of 15mg everolimus alone (n¼3) or combined with a 1-h
infusion of paclitaxel (80mgm
 2). (B) Mean plasma concentration of
everolimus following oral administration of 30mg everolimus alone (n¼4)
or combined with a 1-h infusion of paclitaxel (80mgm
 2). (C) Mean
plasma concentration of paclitaxel following a 1-h infusion of 80mgm
 2
paclitaxel alone (n¼7) or combined with 15 and 30mg everolimus.
Table 4 Pharmacokinetic parameters of everolimus and paclitaxel
Dose level 1 Dose level 2
Everolimus (15mg) Paclitaxel (80mgm
 2) Everolimus (30mg) Paclitaxel (80mgm
 2)
With paclitaxel Alone With everolimus Alone With paclitaxel Alone With everolimus Alone
n¼3 n¼3 n¼3 n¼3 n¼7 n¼4 n¼7 n¼4
tmax (h) 1.0 (1–4) 1.0 (1–1) 0.08 (0.08–0.08) 0.08 (0.08–0.08) 1.0 (1–4) 1.0 (1–1) 0.08 (0.08–0.25) 0.08 (0.08–0.25)
Cmax (ngml
 1) 57.9±35.8 75.2±37.4 1131.7±484.6 2070.0±701.7 94.5±60.1 93.0±28.6 2160.0±684.6 2025.0±691.8
AUClast (nghm
 1) 791.8±346.5 954.9±335.8 1494.1±383.6 2051.0±515.2 1667.8±1000.0 1433.6±1119.8 3913.5±1456.5 3710.1±1575.6
t1/2 (h) 24.6±3.6 29.5±8.5 7.6±3.6 8.3±2.4 27.4±5.6 26.9±7.1 19.7±8.9 12.8±1.8
tmax values are median (range), the other parameters values are mean (s.d.).
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